VEON vs FAMI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 28, 2026

VEON

42.5
AI Score
VS
VEON Wins

FAMI

28.9
AI Score

Investment Advisor Scores

VEON

43score
Recommendation
HOLD

FAMI

29score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric VEON FAMI Winner
Forward P/E 7.9239 0 Tie
PEG Ratio 2.2274 0 Tie
Revenue Growth 16.9% -60.4% VEON
Earnings Growth -78.9% -84.8% VEON
Tradestie Score 42.5/100 28.9/100 VEON
Profit Margin 1.2% 0.0% VEON
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY VEON

Relative Price Performance (Last 90 Days)

VEON 1M: +15.0% · 3M: +42.4% FAMI 1M: -15.9% · 3M: -38.1%

Current Technical Phase

VEON

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (12.6% over 20 days), RSI 72

RSI (14): 72.0 · Price: $75.64

FAMI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 40

RSI (14): 40.1 · Price: $0.13

Fundamentals Snapshot

Metric VEON FAMI
Market Cap — —
Forward P/E 9.0 0.0
Trailing P/E 73.9 —
Revenue (TTM) — —
Revenue Growth 0.2% -0.6%
Gross Margin 0.9% -0.1%
Operating Margin 0.3% -4.9%
EPS 1.00 -30.37
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, VEON is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.